GD2/PSMA Bi-specific CAR-T Cell Therapy
NCT05437315
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumor
Interventions
BIOLOGICAL:
bi-4SCAR GD2/PSMA T cells
Sponsor
Shenzhen Geno-Immune Medical Institute